Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant

Dow Jones

06/23

By Katherine Hamilton

Shares of Armata Pharmaceuticals were higher after the company received an additional $2.5 million in funding from a Pentagon grant.

The stock gained 5% to $7.21 in premarket trading Tuesday. Through Monday's close, the stock was up 9% this year.

The late clinical-stage biotechnology company said the award now totals $28.7 million and is for the development of Armata's clinical candidate AP-SA02.

AP-SA02 is designed as an adjunct treatment of complicated Staphylococcus aureus bacteremia, or Staph infection.

The additional funding is intended to fund activities to support Phase 3 readiness of the treatment.

The money came through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

June 23, 2026 07:34 ET (11:34 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2645725833"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645725833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645725833?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645725833","market":"hk","top_or_hot":-1,"title":"Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Armata Pharmaceuticals were higher after the company received an additional $2.5 million in funding from a Pentagon grant. \n</p>\n<p>\n  The stock gained 5% to $7.21 in premarket trading Tuesday. Through Monday's close, the stock was up 9% this year. \n</p>\n<p>\n  The late clinical-stage biotechnology company said the award now totals $28.7 million and is for the development of Armata's clinical candidate AP-SA02. \n</p>\n<p>\n  AP-SA02 is designed as an adjunct treatment of complicated Staphylococcus aureus bacteremia, or Staph infection. \n</p>\n<p>\n  The additional funding is intended to fund activities to support Phase 3 readiness of the treatment. \n</p>\n<p>\n  The money came through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 07:34 ET (11:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArmata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-23 19:34</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Armata Pharmaceuticals were higher after the company received an additional $2.5 million in funding from a Pentagon grant. \n</p>\n<p>\n  The stock gained 5% to $7.21 in premarket trading Tuesday. Through Monday's close, the stock was up 9% this year. \n</p>\n<p>\n  The late clinical-stage biotechnology company said the award now totals $28.7 million and is for the development of Armata's clinical candidate AP-SA02. \n</p>\n<p>\n  AP-SA02 is designed as an adjunct treatment of complicated Staphylococcus aureus bacteremia, or Staph infection. \n</p>\n<p>\n  The additional funding is intended to fund activities to support Phase 3 readiness of the treatment. \n</p>\n<p>\n  The money came through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 07:34 ET (11:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645725833","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645725833","pubTimestamp":1782214440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Armata Pharmaceuticals were higher after the company received an additional $2.5 million in funding from a Pentagon grant.The stock gained 5% to $7.21 in premarket trading Tuesday. Through Monday's close, the stock was up 9% this year.The late clinical-stage biotechnology company said the award now totals $28.7 million and is for the development of Armata's clinical candidate AP-SA02.AP-SA02 is designed as an adjunct treatment of complicated Staphylococcus aureus bacteremia, or Staph infection.The additional funding is intended to fund activities to support Phase 3 readiness of the treatment.The money came through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARMP":"Armata Pharmaceuticals, Inc."},"translate_title":"Armata Pharmaceuticals股价因额外250万美元政府拨款而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARMP":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Armata Pharmaceuticals were higher after the company received an additional $2.5 million in funding from a Pentagon grant. \n\n\n  The stock gained 5% to $7.21 in premarket trading Tuesday. Through Monday's close, the stock was up 9% this year. \n\n\n  The late clinical-stage biotechnology company said the award now totals $28.7 million and is for the development of Armata's clinical candidate AP-SA02. \n\n\n  AP-SA02 is designed as an adjunct treatment of complicated Staphylococcus aureus bacteremia, or Staph infection. \n\n\n  The additional funding is intended to fund activities to support Phase 3 readiness of the treatment. \n\n\n  The money came through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 07:34 ET (11:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}